Side-by-side comparison of AI visibility scores, market position, and capabilities
OpenEvidence hit $100M+ ARR in under a year serving 430K+ US physicians (40% of all US doctors) at $12B valuation ($700M raised); fastest-growing physician AI platform, founded 2022 Miami.
OpenEvidence is an AI clinical evidence platform founded in 2022 and headquartered in Miami, Florida. Built specifically for physicians, the platform applies large language models trained on peer-reviewed medical literature to deliver instant, evidence-backed answers to clinical questions at the point of care. Its founding mission is to democratize access to the best available medical evidence so that every physician can practice at the highest standard, regardless of institution or specialty.\n\nThe platform aggregates and synthesizes peer-reviewed studies, clinical guidelines, and drug databases, presenting structured answers with citations that meet physician-grade accuracy standards. Unlike general-purpose AI assistants, OpenEvidence is purpose-built for clinical workflows. It is free to use for physicians, with monetization routed through pharmaceutical and healthcare industry partners who value the platform's direct access to practicing clinicians.\n\nOpenEvidence has achieved remarkable traction, reaching over 430,000 US physicians — approximately 40% of the entire US physician population — making it the fastest-growing physician AI platform on record. The company crossed $100M ARR in under a year from launch and earned a $12 billion valuation on $700 million in total funding. This trajectory places OpenEvidence among the fastest-scaling healthcare AI companies globally and signals a structural shift toward AI-assisted clinical decision-making at the point of care.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.